Gipper: Gerald is only addressing a portion of the reason for the sell off. Yes, the billion share vote is part of the reason people are concerned, but it is because shareholder value didn't appear the way many longs expected it would in September. Many longs were expecting the July Conferences to be Lympro's kick off to the world. But management didn't have the data on time and we didn't get the bang we could have. (Poor execution and communication) And then at the end of summer we were led to believe we'd get a "classic partner" like J&J with up front money. If these things had happened, we'd be in the .20 to .40 cent range right now and no one would care about the billion share vote.
Gerald's problem is that he isn't really in tune with the real problem. The billion shares isn't at the heart of the problem. The elephant in the room is that Gerald led us to believe we'd get a "classic partner" for LymPro, but instead we got a master service agreement with ICON!! The billion share vote is simply salt on the wounds, not the wound itself.
My concerns about these issues haven't been "lies" or "disinformation."
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links